Is Supernus a public company?
Supernus Pharmaceuticals is an authentic, publicly traded corporate entity listed on the Nasdaq Global Select Market under the ticker symbol SUPN. As a fully reporting public enterprise, it complies strictly with United States Securities and Exchange Commission regulations, regular quarterly financial disclosures, and corporate governance standards, enabling institutional and retail investors worldwide to buy and sell its common shares on the open market.
Related FAQs
Actor and Parkinson's disease research advocate Michael J.
Supernus Pharmaceuticals operates in the specialty pharmaceutical sector focusing on central nervous system disorders, encountering competition from numerous established drug developers and generic manufacturers.
Yes, Stanley Black & Decker (trading under the ticker SWK) has a long-standing corporate history of executing stock splits throughout its multi-decade trajectory as a premier global industrial tool and hardware manufacturer.
Supernus Pharmaceuticals operates primarily as a specialty pharmaceutical enterprise rather than a traditional early-stage biotechnology research firm.
Supernus Pharmaceuticals has executed key strategic acquisitions to bolster its neurology and neuropsychiatry product portfolio and diversify its revenue streams.
"Swig" is not a widely recognized publicly traded stock ticker, though it is commonly confused with "Swiggy," a major consumer technology company based in India.
Supernus Pharmaceuticals, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Select Market under the ticker symbol SUPN in May 2012.
Supernus Pharmaceuticals operates in rigorous compliance with federal and international pharmaceutical regulations, medical ethics standards, and corporate compliance frameworks.
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals anticipates a progressive future growth outlook driven by the expansion of its specialized neurology and psychiatry product portfolio, including treatments for epilepsy, attention deficit hyperactivity disorder, and centra...
Swire Properties Limited is a major premier developer, owner, and operator of mixed-use commercial and residential properties, primarily centered in Hong Kong and the Chinese mainland.
Supernus Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
Evaluating the profitability profile of Supernus Pharmaceuticals involves analyzing fluctuating quarterly earnings reports, research and development expenditures, and commercial product sales revenue.
The five-two-one rule or similar numerical clinical heuristics for Parkinson's disease assist neurologists and patients in monitoring progressive symptom management, medication timing schedules, and multidisciplinary therapy interventions.
A 70-year-old individual diagnosed with stage 3 chronic kidney disease can often live a normal lifespan, provided the condition is actively managed and monitored through proper lifestyle modifications, blood pressure control, and dietary adjustmen...
During the course of Joe Biden's presidency, the stock market experienced strong upward momentum alongside broader macroeconomic shifts, with the Dow Jones Industrial Average rising by roughly 40.
Levodopa, frequently administered in combination with carbidopa, is universally recognized as the clinical gold standard pharmacological treatment for managing the motor symptoms of Parkinson's disease.
Supernus Pharmaceuticals specializes in developing and commercializing specialized central nervous system medications designed to treat psychiatric and neurological disorders.
Supernus Pharmaceuticals maintains a solid reputation within the specialty healthcare and pharmaceutical sector, anchored by its diverse portfolio of FDA-approved medications addressing complex central nervous system disorders.
Supernus Pharmaceuticals, Inc. was officially founded and established in 2005 through a management buyout of specialty pharmaceutical assets from Shire plc.